NEWTOWN, Pa.--(Quinnova Pharmaceuticals, Inc., a specialty pharmaceutical company that develops and markets novel topical delivery platform-based prescription drugs, today announced the launch of its NEOSALUSTM CREAM. NEOSALUS CREAM, the latest addition to Quinnova’s NEOSALUS brand, is a prescription product with anti-inflammatory properties that can be used without age or long-term use restrictions for the treatment of a variety of chronic inflammatory skin conditions like atopic dermatitis, contact dermatitis, and hand eczema. The non-irritating cream is gentle, safe, and fragrance- and alcohol-free. Using the Proderm Technology Delivery System (“Proderm”), NEOSALUS CREAM complements Quinnova’s NEOSALUS product line.)--
“I routinely use NEOSALUS in my dermatology office”
“I routinely use NEOSALUS in my dermatology office,” says Firas Hougeir, M.D. “I appreciate the versatility of the product and being able to choose between the foam and the cream for my patients. The cosmetic characteristics of the product have led to better patient compliance and treatment outcomes. NEOSALUS has been a strong addition to my armamentarium, allowing me to decrease steroid use in my patients and increase their tolerance of potentially irritating treatment regimens.”
NEOSALUS repairs, protects, and hydrates the skin. NEOSALUS CREAM restores dysfunctional skin by replenishing lost physiological lipids, functions as a protectant to reduce the penetration of irritants, and improves skin hydration. Patients with chronic inflammatory skin conditions often experience dry, itchy, and scaly skin, with compromised skin barrier decreasing protection against irritants and infection. These disorders are characterized by cycles of exacerbations and remissions. NEOSALUS’ anti-inflammatory properties help reduce the frequency and severity of flare-ups, decrease reliance on corticosteroids, and complement other simultaneous treatments.
The cosmetically elegant, non-comedogenic NEOSALUS CREAM has been formulated for easier application to smaller surface areas, like the face, and targeted application on other body areas, while the earlier launched NEOSALUS FOAM is suited for application to larger body areas.
“We’re pleased to offer the NEOSALUS CREAM as a significant addition to the treatment options for chronic inflammatory skin disorders,” says Jeffrey S. Day, Founder, President, and CEO of Quinnova Pharmaceuticals. “Clinicians, in general, are dissatisfied with current topical treatment options for chronic skin conditions, often citing poor efficacy and low patient compliance. We developed the NEOSALUS CREAM in order to cater to the specific needs of our doctors and their patients, realizing the necessity of providing a safe, effective, and more convenient offering for atopic dermatitis and hand eczema patients.”
Many products that treat chronic inflammatory skin conditions are alcohol-based, which can lead to more irritation and poor patient compliance. Proderm Technology, on the other hand, is comprised of a mixture of water and lipids, and does not contain alcohol. Proderm is effective because of its ability to ‘Protect – Repair – Hydrate’ the skin with its ease of application and rapid absorption. It protects from external irritants by forming a physical barrier, facilitates the repair of the skin by providing essential nourishment in the form of free fatty acids, and hydrates the skin. Proderm is fragrance-free, non-comedogenic, non-alcohol based, and non-greasy.
About Quinnova Pharmaceuticals, Inc.
Quinnova Pharmaceuticals, Inc., founded in 2005 and based in Newtown, Pa., is a specialty pharmaceutical company focused on the development and commercialization of prescription drug products, using its proprietary and innovative topical drug delivery platforms. Quinnova’s current product development activities are aimed at using already-proven safe and effective pharmaceutical ingredients and incorporating them in elegant, unique, patent-protected, customer-friendly delivery systems. This strategy is augmented by the development of medical devices increasing the current portfolio of products. Quinnova focuses on new pharmaceutical products that have a relatively short bench-to-market timeline and a low-development risk profile. Its penetration of the U.S. market is accompanied by a growing presence in the international market, mostly through a business development strategy of licensing and utilizing partners to promote Quinnova products. www.Quinnova.com